Skip to main content

Glomerular Filtration Rate

1
Pipeline Programs
2
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Temple Therapeutics
Temple TherapeuticsNetherlands - Geleen
1 program
1
sirolimusPhase 4
MediBeacon
MediBeaconGermany - Mannheim
4 programs
LumitraceN/A1 trial
LumitraceN/A1 trial
Below target dose MP-3180PHASE_11 trial
MP-3180PHASE_11 trial
Active Trials
NCT07349797Not Yet Recruiting15Est. Jan 2027
NCT07335614Not Yet Recruiting25Est. Jan 2027
NCT02098187Completed16Est. Mar 2014
+1 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
MediBeaconBelow target dose MP-3180
MediBeaconMP-3180
MediBeaconLumitrace
MediBeaconLumitrace

Clinical Trials (4)

Total enrollment: 72 patients across 4 trials

NCT02098187MediBeaconBelow target dose MP-3180

Pharmacokinetics of MP-3180 and Use of Noninvasive Fluorescence Detection Device in Healthy Volunteers

Start: Mar 2014Est. completion: Mar 201416 patients
Phase 1Completed
NCT02098174MediBeaconMP-3180

Pharmacokinetics of MP-3180 in Healthy Volunteers

Start: Nov 2013Est. completion: Jan 201416 patients
Phase 1Completed
NCT07335614MediBeaconLumitrace

Evaluation of Protein Loading on Measurement of Renal Reserve

Start: May 2026Est. completion: Jan 202725 patients
N/ANot Yet Recruiting
NCT07349797MediBeaconLumitrace

MediBeacon® Transdermal GFR System for the Evaluation of Kidney Function in Adults With Heart Failure

Start: Apr 2026Est. completion: Jan 202715 patients
N/ANot Yet Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.